The Role of Cuproptosis Related Key Genes in Ovarian Cancer and the Construction of a Prognostic Model
Abstract
Objective
Using ovarian cancer datasets from public databases, identify copper death-related genes in ovarian cancer tissues and construct a clinical prognostic risk scoring model for ovarian cancer patients based on these genes.
Methods
We downloaded the OC data of TCGA, the GSE26193, GSE63885 dataset from GEO and retrieved 10 cuproptosis related genes (CRGs) and analyzed their chromosomal localization, expression correlation, and mutation patterns based on the datasets. Using these genes, we clustered the OC samples to identify different molecular subtypes of copper induced death. We analyzed the differential genes and functional enrichment between different subtypes and obtained feature genes with predictive ability for prognosis through survival regression analyses. Based on these feature genes, we constructed a risk scoring model and incorporated the clinical characteristics ofpatients to jointly predict their survival rate.
Results
In ovarian cancer samples, 10 copper death-related genes can stably divide the samples into two molecular subtypes, and there are significant differences in clinical and immune characteristics and drug sensitivity between them. After further screening, seven prognostic genes (RARRES1、CXCL10、PI3、CXCL11、THEMIS2、GBP2、RPL39L) were obtained, and the risk model based on them combined with age predicted that the AUC of patients' 1-, 3-, and 5-year survival rates were all greater than 0.7, showing good clinical application prospects.
Conclusion
The mechanism of cuproptosis and its key genes might become therapeutic targets for ovarian cancer. The subtypes of cuproptosis provide a theoretical basis for personalized clinical treatment. The predictive model constructed by key prognostic genes has promising clinical application effects.
Keywords: Ovarian cancer, Cuproptosis-related genes, Immune infiltration
Full Text:
PDFReferences
TORRE L A, TRABERT B, DESANTIS C E, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin, 2018, 68(4): 284-296. doi: 10.3322/caac.21456.
GELISSEN J H, ADJEI N N, MCNAMARA B, et al. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. Ann Surg Oncol, 2023, 30(9): 5597-5609. doi: 10.1245/s10434-023-13757-0.
ZHAO S, ZHANG X, GAO F, et al. Identification of copper metabolism-related subtypes and establishment of the prognostic model in ovarian cancer. Front Endocrinol (Lausanne), 2023, 14: 1145797. doi: 10.3389/fendo.2023.1145797.
TANG D, CHEN X, KROEMER G. Cuproptosis: a copper-triggered modality of mitochondrial cell death. Cell Res, 2022, 32(5): 417-418. doi: 10.1038/s41422-022-00653-7.
GUO F, YANG Z, KULBE H, et al. Inhibitory effect on ovarian cancer ALDH+ stem-like cells by Disulfiram and Copper treatment through ALDH and ROS modulation. Biomed Pharmacother, 2019, 118: 109371. doi: 10.1016/j.biopha.2019.109371.
TSVETKOV P, COY S, PETROVA B, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science, 2022, 375(6586): 1254-1261. doi: 10.1126/science.abf0529.
BIAN Z, FAN R, XIE L. A Novel Cuproptosis-Related Prognostic Gene Signature and Validation of Differential Expression in Clear Cell Renal Cell Carcinoma. Genes (Basel), 2022, 13(5): 851. doi: 10.3390/genes13050851.
LV H, LIU X, ZENG X, et al. Comprehensive Analysis of Cuproptosis-Related Genes in Immune Infiltration and Prognosis in Melanoma. Front Pharmacol, 2022, 13: 930041. doi: 10.3389/fphar.2022.930041.
XU J, HU Z, CAO H, et al. Multi-omics pan-cancer study of cuproptosis core gene FDX1 and its role in kidney renal clear cell carcinoma. Front Immunol, 2022, 13: 981764. doi: 10.3389/fimmu.2022.981764.
WANG H, YANG Z, HE X, et al. Cuproptosis related gene PDHB is identified as a biomarker inversely associated with the progression of clear cell renal cell carcinoma. BMC Cancer, 2023, 23(1): 804. doi: 10.1186/s12885-023-11324-0.
GAO F, YUAN Y, DING Y, et al. DLAT as a Cuproptosis Promoter and a Molecular Target of Elesclomol in Hepatocellular Carcinoma. Curr Med Sci, 2023, 43(3): 526-538. doi: 10.1007/s11596-023-2755-0.
SCHULZ V, BASU S, FREIBERT S A, et al. Functional spectrum and specificity of mitochondrial ferredoxins FDX1 and FDX2. Nat Chem Biol, 2023, 19(2): 206-217. doi: 10.1038/s41589-022-01159-4.
WU C C, LI C J, LIN L T, et al. Cuproptosis-Related Gene FDX1 Identified as a Potential Target for Human Ovarian Aging. Reprod Sci, 2024, 31(12): 3929. doi: 10.1007/s43032-024-01573-0.
PAIK E S, KIM T H, CHO Y J, et al. Preclinical assessment of the VEGFR inhibitor axitinib as a therapeutic agent for epithelial ovarian cancer. Sci Rep, 2020, 10(1): 4904. doi: 10.1038/s41598-020-61871-w.
WANG R, YE X H, ZHAO X L, et al. Development of a five-gene signature as a novel prognostic marker in ovarian cancer. Neoplasma, 2019, 66(3): 343-349. doi: 10.4149/neo_2018_180705N447.
ZHANG Y, CHEN Y, ZHANG L, et al. lncRNA CLRN1-AS1 reduces adhesion ability of human trophoblasts via CXCL10/CXCL11. Placenta, 2023, 140: 47-59. doi: 10.1016/j.placenta.2023.07.003.
LI W, MA J A, SHENG X, et al. Screening of CXC chemokines in the microenvironment of ovarian cancer and the biological function of CXCL10. World J Surg Oncol, 2021, 19(1): 329. doi: 10.1186/s12957-021-02440-x.
LI Y, LI H, YANG B, et al. Clinical significance of PI3 and HLA-DOB as potential prognostic predicators for ovarian cancer. Transl Cancer Res, 2020, 9(2): 466-476. doi: 10.21037/tcr.2019.11.30.
GAO Y, QI Y, SHEN Y, et al. Signatures of tumor-associated macrophages correlate with treatment response in ovarian cancer patients. Aging (Albany NY), 2024, 16(1): 207-225. doi: 10.18632/aging. 205362.
WANG X, WANG S S, ZHOU L, et al. A network-pathway based module identification for predicting the prognosis of ovarian cancer patients. J Ovarian Res, 2016, 9(1): 73. doi: 10.1186/s13048-016-0285-0.
ROHOZINSKI J, ANDERSON M L, BROADDUS R E, et al. Spermatogenesis associated retrogenes are expressed in the human ovary and ovarian cancers. PLoS One, 2009, 4(3): e5064. doi: 10.1371/journal. pone.0005064.
Refbacks
- There are currently no refbacks.
